- Home
- AGIO vs CLOV Comparison
AGIO vs CLOV Comparison
Compare AGIO & CLOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- CLOV
- Stock Information
- Founded
- AGIO 2007
- CLOV 2014
- Country
- AGIO United States
- CLOV United States
- Employees
- AGIO N/A
- CLOV N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- CLOV Medical Specialities
- Sector
- AGIO Health Care
- CLOV Health Care
- Exchange
- AGIO Nasdaq
- CLOV Nasdaq
- Market Cap
- AGIO 1.4B
- CLOV 1.5B
- IPO Year
- AGIO 2013
- CLOV N/A
- Fundamental
- Price
- AGIO $35.00
- CLOV $2.78
- Analyst Decision
- AGIO Buy
- CLOV Strong Buy
- Analyst Count
- AGIO 6
- CLOV 3
- Target Price
- AGIO $57.40
- CLOV $4.83
- AVG Volume (30 Days)
- AGIO 840.6K
- CLOV 9.9M
- Earning Date
- AGIO 07-31-2025
- CLOV 08-05-2025
- Dividend Yield
- AGIO N/A
- CLOV N/A
- EPS Growth
- AGIO N/A
- CLOV N/A
- EPS
- AGIO 11.13
- CLOV N/A
- Revenue
- AGIO $40,875,000.00
- CLOV $1,486,540,000.00
- Revenue This Year
- AGIO $18.94
- CLOV $38.62
- Revenue Next Year
- AGIO $201.70
- CLOV $22.21
- P/E Ratio
- AGIO $3.15
- CLOV N/A
- Revenue Growth
- AGIO 30.57
- CLOV 15.62
- 52 Week Low
- AGIO $23.42
- CLOV $1.50
- 52 Week High
- AGIO $62.58
- CLOV $4.87
- Technical
- Relative Strength Index (RSI)
- AGIO 38.99
- CLOV 41.46
- Support Level
- AGIO $37.09
- CLOV $2.87
- Resistance Level
- AGIO $39.12
- CLOV $3.00
- Average True Range (ATR)
- AGIO 1.78
- CLOV 0.19
- MACD
- AGIO -0.67
- CLOV -0.03
- Stochastic Oscillator
- AGIO 9.16
- CLOV 2.58
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About CLOV Clover Health Investments Corp.
Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. It operates in one segment: Insurance, through which it offers PPO and HMO plans to Medicare Advantage members in several states.